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Haematopoietic and lymphoid neoplasms like 
lymphomas and leukemias are common occurrences 
both among adults and children. Fortunately, a 
signifi cant number of these disorders are curable 
with modern chemotherapeutic regimen. First step 
is a precise laboratory diagnoses using modern 
diagnostic tools. Besides routine morphology 
diagnoses of these disorders has been revolutionized 
by immunological and genetic analyses. Quick 
transfer of  modern tools from research lab to 
diagnostic lab and then to bedside is unprecedented 
and unmatched by developments in any other organ 
system. Indeed they are the bench mark from where 
a lot needs to be learnt by others. 
The Aga Khan University Hospital Clinical 
Laboratory is equipped with required human and 
physical resources. For example, a comprehensive 
‘Immunohistochemical’, ‘Flow Cytometric’ and 
‘Cytogenetic ‘ facility along with highly qualified 
and dedicated faculty to ensure precise diagnoses 
of these disorders from where begins the proper 
treatment of the patient follows.
In this issue we have mainly focused on the 
diagnostics of tumour screening and highlighted new 
tumour markers. 
Dr Shahid Pervez,
Professor & Consultant Histopathology,
Department of Pathology & Microbiology,
Aga Khan University Hospital, 
Editorial
Immunophenotyping by Flowcytometry
Introduction
Over the past few years, the role of fl owcytometry 
in haematology especially in malignant 
haematology has become inevitable. It has made 
a transition from being an experimental device 
of colossal magnitude confi ned to research 
laboratories, into a bench-top instrument of 
indispensible use in the diagnosis, classifi cation and 
monitoring disease response. 
Defi nition
The word ‘cyto’ means cell and ‘metry’ is 
measurement. So fl owcytometry is measuring 
properties of cells in a fl owing system. It evaluates 
optical and fl uorescent characteristics of a cell or 
any other particle such as nuclei, microorganisms, 
chromosome preparations and latex beads. 
When a fl uorescent dye is conjugated to a 
monoclonal antibody, it can be used to identify a 
particular cell type based on the individual antigenic 
surface markers of the cell.
History
The original fl owcytometer was the Coulter
counter (Beckman Coulter M) invented by 
Wallace Coulter in the 1950s. It was in 
1968, when the fi rst fl uorescence-based fl ow 
cytometry device (ICP 11) was developed 
by Wolfgang Göhde from the University of 
Münster, Germany and later commercialized 
by German developer and manufacturer Partec 
through Phywe AG in Göttingen. After a decade, 
in 1978, at the Conference of the American 
Engineering Foundation in Pensacola, Florida, 
the name fl owcytometry was given to this 
methodology. Before that it was known as pulse 
cytophotometry. 
Advancement in the field of immunophenotyping 
by flowcytometry with the availability of a wide 
variety of antibodies and flourochromes
(a fluorescent chemical compound that can 
re-emit light upon light excitation) has led to 
more accurate and precise identification
of cells.
Sidra Asad Ali
Haematology
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(antigens) present on the surface, cytoplasm or 
nucleus of the cell. When these fl ourochome labeled 
cells are passed through a light beam, the fl uorescent 
molecules absorbs light and caused the electrons to 
get into higher energy state. This excited electron 
quickly decays into a ground state or resting state 
and emit excess energy at a higher wave length.  This 
transition of energy by different fl ourochromes allow 
multiple characteristics of the cells to be measured 
including  cell size, cytoplasmic content, complexity, 
DNA or RNA properties, variety of  membrane and 
intracellular proteins.
Propidium iodide, phycoerythrin, and fl uorescein are 
the dyes which are commonly used.  Tandem dyes 
with internal fl uorescence resonance energy transfer 
can create even longer wavelengths and more colors.
Specimen 
Flowcytometry is used for immunophenotyping of a 
variety of specimens, including whole blood, bone 
marrow aspirate, serous cavity fl uids, cerebrospinal 
fl uid, urine, fi ne needle aspiration and biopsies of 
lymph node and from other lymphoid tissues. 
Principle
A beam of monochromatic light, usually from laser, 
intersects cells which are hydrodynamically-focused 
and are allowed to pass one by one through the point 
of interrogation. As soon as the interaction occurs, 
light is emitted in all directions and captured via 
detectors that direct the light to a series of fi lters and 
dichroic mirrors that isolate particular wavelength 
bands. These light signals are then detected by 
photomultiplier tubes and computerized for further 
analysis. 
There are number of detectors that are placed at 
different points where the stream passes through the 
light beam. The one which is placed in line with the 
light beam is called forward side scatter and those 
placed perpendicular to light beam are known as side 
scatter. There are multiple fl uorescence emission 
detectors as well which are placed at different positions.
Fluorochrome
It is a fl uorescent dye is conjugated monoclonal 
antibodies, which then bind to specifi c proteins 
Ref: Flow Cytometry: Principles and Clinical Applications in Hematology. Clinical Chemistry. August 2000 vol. 46 no. 8 1221-1229
Field
Hematology
Immunology
Oncology
Blood banking
Genetic disorders
Clinical application Common characteristic measured
Leukocyte surface antigens
TdT, MPO
CD34
CD25, CD69
RNA
Eosin-5′-maleimide-labeled intact red blood 
cells
IgG, IgM
IgG
Complement, IgG
Hemoglobin F, rhesus D
IgG, IgM
CD3, circulating OKT3
HLA-B27
CD4, CD8
DNA
Ki-67, PCNA
Erythrocyte surface antigens
Forward and side scatter, leukocyte surface 
antigens
CD55, CD59
CD11/CD18 complex
Leukemia and lymphoma phenotyping
Identifi cation of prognostically important 
subgroups
Hematopoietic progenitor cell enumeration
Diagnosis of systemic mastocytosis
Reticulocyte enumeration
Hereditary Spherocytosis
Autoimmune and alloimmune disorders
Anti-platelet antibodies
Anti-neutrophil antibodies
Immune complexes
Feto-maternal hemorrhage quantifi cation
Histocompatibility cross-matching
Transplantation rejection
HLA-B27 detection
Immunodefi ciency studies
DNA content and S phase of tumours
Measurement of proliferation markers
Immunohematology
Assessment of leukocyte contamination of 
blood products
PNH
Leukocyte adhesion defi ciencya
Table:1 Applications of Flowcytometry:
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Immunophenotyping of Hematological 
Malignancies
The use of fl owcytometry in haematological 
malignancies has a pertinent role. To begin with, only 
a restricted panel of monoclonal antibodies were used 
and it was largely focused on further characterization 
and determining the lineage (lymphoid versus 
myeloid origin of blast cells in acute leukemia) 
after the diagnosis of leukemia/lymphoma. Over the 
period of time, an extensive range of fl ourchomes 
have been developed and it is now used not only for 
diagnosis and classifi cation but also for assessing 
prognosis, response of disease and for determining 
minimal residual disease with the help of individual 
immunophenotypic markers.
Limitations
Presence of particles in single-cell suspension only 
and properties of the fl uorescent molecules used to 
stain the cells and photon statistics of fl uorescence 
from the stained and unstained populations of cells 
are the few drawbacks of the methodology. Lack of 
standardization in and instrument set-up and assay is 
major limitation. Attention has been given and lot of 
efforts has been done to introduce standard protocols. 
Another limitation is subjectivity of the operator 
who gates the specifi c population, as the substantial 
amount of information generated which makes 
interpretation intricate.  An important advancement 
in this regard is the development of gating tools, 
automated multidimensional visualization as well as 
post-analysis data aggregation models. 
Future Directions
There have been a lot of advancements which has 
improved the instrument, conjugated antibodies 
and the software. Image cytometry is the recent 
progress, which has combined modern multicolor 
fl owcytometry with microscopy or transcripational 
profi ling.
Cytometry by mass cytometer, utilizes time-of-
fl ight mass spectrometry to discriminate a set of 
more than 40 heavy metal ion–labeled antibodies 
without the shortcomings of fl uorescence spillover 
or autofl uorescence (Bendall et al., 2011, 2012). The 
Fludigm Biomark system allows the quantifi cation 
of mRNA levels using highly multiplexed real-
time PCR using special microfl uidic devices, thus 
allowing detection of up to more than 100 gene 
transcripts from a single cell.
Summary
Flowcytometer is a powerful tool for measuring 
multiple characteristics of a single cell. With the 
progression into smaller, user friendly and less 
expensive device and with also introduction of wide 
variety of antibodies, the use of fl owcytometer has 
become ineluctable in the diagnosis and management 
of broad spectrum of diseases. 
Chronic Lymphocytic Leukaemia: Diagnosis 
and Prognostic Factors
Chronic lymphocytic leukaemia (CLL) is a chronic 
B-cell lymphoproliferative disorder. It is more 
prevalent in the western population and is the 
most common type of leukaemia in the west. CLL 
is more commonly seen in men and in the 
elderly.
Diagnosis
Most of the patients with CLL are diagnosed 
incidentally based on lymphocytosis on a 
complete blood count.  However, some patients 
may present with lymphadenopathy, systemic 
symptoms such as fever, night sweats and 
weight loss or the symptoms of anemia or 
infection. 
The diagnosis of CLL requires presence of >5 
x 109/l circulating clonal B lymphocytes with 
characteristic morphology persisting for >3 months 
and a characteristic immunophenotype detected by 
fl ow cytometry.  
Dr Farheen Karim
Haematology
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Tumour Markers
Introduction
Current clinical practice has a growing impetus on early 
diagnosis, proper prognostication and screening for 
malignancy in asymptomatic groups. Tumour markers 
are assuming a growing role in all aspects of cancer care, 
starting  from screening to follow-up after treatment. 
These markers are a structurally and functionally diverse 
group which includes amines, glycoproteins, hormones, 
enzymes, paraproteins and tumour associated antigens 
found in the blood, urine or tissues of patients with 
Dr Syed Talha Naeem
Chemical Pathology
certain types of cancer. They are typically produced by 
tumour cells, but in some cases they may be produced 
by the body in response to malignancy or to certain 
benign conditions. Tumour markers are not elevated in 
all cancer patients, particularly patients with early-stage 
cancer. They are measured qualitatively or quantitatively 
by chemical, immunological, or molecular biological 
methods. The characteristics of an ideal tumour marker 
are shown in Table 1. 
Morphologically, lymphocytes in CLL are small 
in size with scanty cytoplasm. The nucleus shows 
clumped chromatin and the nucleolus is not visible. 
There is also presence of many smear or smudge 
cells on the peripheral fi lm (as shown in Figure 1). 
Immunophenotyping shows expression of 
CD19, CD20,  CD23 and CD5. There is weak 
expression of surface membrane immunoglobulin 
with light chain restriction i.e. only a single 
immunoglobulin light chain ( kappa or lambda) 
is expressed not both, confirming the clonal 
nature of these cells. Additionally, CLL cells are 
usually negative for cyclin D1 and CD10. FMC7, 
CD22, and CD79b are also commonly negative or 
weakly expressed.
Bone marrow examination is not essential 
for the diagnosis of CLL, but is mandatory 
to define complete response after treatment. 
It is also indicated in determining the cause 
of cytopenias and assessing the pattern of 
involvement by the lymphoid cells (diffuse, 
nodular or interstitial).
Lymph node biopsy is only indicated when there is 
diagnostic uncertainty or clinical suspicion of 
lymphomatous transformation known as Ritcher’s 
transformation.
Prognosis
The various factors that predict poor prognosis in 
CLL include the following:
 Advanced stage of disease (Binet B and C and  
 Rai II and IV) 
  Diffuse pattern of bone marrow infi ltration 
  No response to treatment
 Male sex
 Unmutated Immunoglobulin heavy chain (IgVH)
 High Zap-70 and CD 38 expression detected by 
 fl ow cytometry
 High LDH and Beta-2 microglobulin levels 
 P53 or deletion 17p detected by FISH has the 
 worst prognosis. Detection of 11q23 deletions 
 and trisomy 12 is also a bad prognostic marker. 
 Presence of 13qDel as a sole abnormality confers 
 a good prognosis.
  Rapid lymphocyte doubling time 
Detection of these prognostic factors can 
help in predicting the course of illness in a 
patient.
Figure 1: Peripheral fi lm of a patient with CLL showing lymphocytosis 
and smear cells (AKUH Lab)
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How are Tumour Markers Used?
Clinical uses can be broadly classifi ed into 4 groups.
1. Screening and early detection: Screening 
refers to testing for cancer in people who have no 
symptoms of the disease. Early detection is fi nding 
cancer at an early stage, when it’s less likely to have 
spread and is easier to treat. Tumour markers were 
fi rst developed to screen for cancer – to look for 
cancer in people without symptoms – but very few 
markers have been shown to be helpful in this way. 
A perfect tumour marker would be one that could be 
used as a cancer screening blood test for all people. 
The tumour marker would only be elevated in people 
with cancer. At this time there are no tumour marker 
tests that work like this.
2. Diagnostic confi rmation: By and large, tumour 
markers cannot be construed as primary modalities 
for the diagnosis of cancer, mainly because of the 
lack of suffi ciently high specifi city and sensitivity. 
Their main clinical utility is as a laboratory test to 
support the diagnosis or in follow-up of patients 
being treated for malignancy. Attempts to improve 
the sensitivity and/ or specifi city of tumour markers 
have led to combination of tumour markers with 
other procedures (e.g., combination of Carbohydrate 
antigen (CA) 125 with ultrasonography for early 
detection of ovarian malignancy) or to refi ning the 
evaluation criteria for tumour markers (e.g., PSA 
density or PSA velocity or age-specifi c PSA cut off 
ranges for early detection of prostate cancer). 
3. Prognosis and prediction of therapeutic 
response: Tumour marker levels, in certain 
situations, refl ect tumour burden in the body and 
hence can be used in staging, prognostication or 
prediction of response to therapy. Markers usually 
increase with progressive disease, decrease with 
remission and do not change signifi cantly with stable 
disease. Tumour marker kinetics is generally more 
important than individual values.
4. Monitoring disease and recurrence: 
Monitoring disease is, perhaps, the most common 
clinical use of serum tumour markers. Rising 
trend in serum levels may detect recurrence of 
disease well before any clinical or radiological 
evidence of disease is apparent (“biochemical 
recurrence”).
When are Tumour Markers Measured?
It is imperative to remember that though an 
aggressive investigative approach may be warranted 
on the basis of raised tumour marker values, 
treatment cannot be initiated without undisputable 
documentation (often histological) of the disease. 
A single value or test is unreliable in itself.  It is 
noteworthy that in most situations, elevations of 
markers in nonmalignant diseases are often transient, 
whereas elevations associated with cancer either 
remain constant or continuously rise. Ordering serial 
testing can help detect falsely elevated levels due to 
transient elevation. 
Knowledge of the assay method is important in 
interpretation of either an abnormal value or a serial 
change in tumour marker values. Various methods of 
detection have their own specifi c cut off values and 
sensitivities. Thus, for any set of serial values to be 
meaningful, they have to come from the same assay 
methods and preferably from the same laboratory. 
In certain situations of so-called biochemical 
recurrences, it is always useful to go back to the 
laboratory to confi rm this. In tumours with multiple 
raised markers measured prior to defi nitive therapy, 
Table 1: Characteristics of an Ideal Tumour Marker 
Remarks
Detectable only in one tumour type
Non-detectable in physiological or benign disease 
states
Suffi cient time for alteration of natural course of 
disease
Prognostic and predictive utility of the tumour marker
Frequent serial monitoring of the marker levels after 
5-6 half lives
Applicability as screening test
Acceptability by target population
Characteristics
Highly specifi c
Highly sensitive
Long lead-time
Levels correlate with tumour burden
Short half-life
Simple and cheap test
Easily obtainable specimens
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the marker showing highest elevation should be used 
for follow-up.
Tumour marker kinetics should always be factored 
before repeating the tests. Too frequent estimation 
of the tumour marker may misrepresent the course 
of the disease due to distribution and elimination 
kinetics. As a general guideline, the time interval 
between serial determinations should be three 
months; but in case of an abnormal value, a repeat 
estimate can be ordered within two to four weeks 
irrespective of the initial reading. 
The success of surgical removal of a tumour as 
determined by tumour marker concentrations is 
ideally ascertained after a period not less than 5-6 
half-lives, to allow tumour marker levels to make a 
plateau or fall to normal. This period may be even 
longer in case of treatment with chemotherapy 
or radiotherapy, wherein the therapeutic effects 
themselves are manifested after a lag period. 
Patient characteristics affect the tumour marker 
values to a signifi cant degree. The anticipated fall 
in levels may not be evident in situations where the 
metabolism or excretion of the tumour marker is 
altered, like in patients with renal or liver disease, 
depending on whether the tumour marker is removed 
through glomerular fi ltration or metabolized by the 
liver. For example, serum CEA is often elevated in 
patients with liver diseases because the metabolism 
of CEA by the diseased liver is subnormal. False 
Table 2: Tumour markers tested in the section of Chemical Pathology, AKUH
Marker
Alpha fetoprotein 
(AFP)
β-hCG
Carcinoembryonic 
antigen (CEA)
 
CA 125
PSA
CA 15-3
CA 19-9
Calcitonin
Beta-2-
microglobulin
Thyroglobulin
Malignancy
Hepatoma, Germ cell tumours
Choriocarcinoma, Germ cell 
tumours
Colorectal, stomach, pancreas
Ovarian
Prostate
Breast
Colorectal, stomach, pancreas
Thyroid (Medullary carcinoma)
Myeloma, chronic lymphocytic 
leukemia (CLL), and some 
lymphomas (including 
Waldenstrom macroglobulinemia)
Thyroid (papillary, follicular)
Nonmalignant conditions
Viral hepatitis, liver injury, infl ammatory bowel 
disease, pregnancy
Testicular failure, marijuana smokers, pregnancy
Smokers, infl ammatory bowel disease, hepatitis, 
cirrhosis, pancreatitis, gastritis
Peritoneal irritation, endometriosis, pelvic infl am-
matory disease, hepatitis, pregnancy
Prostatitis, benign prostatic hyperplasia
Liver cirrhosis, tuberculosis, sarcoidosis, benign 
breast disease, pelvic infl ammatory disease, 
endometriosis, systemic lupus erythematosus, 
lactation and pregnancy
Biliary tract obstruction, cholangitis, infl ammatory 
bowel disease, acute or chronic pancreatitis, liver 
cirrhosis, cystic fi brosis, thyroid disease
-
Kidney disease and hepatitis
-
9VOL. 39, ISSUE 1SEPTEMBER 2013
Dr Noreen Sherazi
Chemical Pathology
Role of Chemical Pathology in Screening and 
Diagnosis of Multiple Myeloma
Multiple myeloma (MM) is characterized by the 
neoplastic proliferation of a single clone of plasma 
cells producing a monoclonal immunoglobulin. 
Normally, plasma cells produce antibodies and 
play a key role in the immune function. However, 
uncontrolled growth of these cells leads to bone 
pain and fractures, anemia, infections, and other 
complications. In the United States, about four 
people per 100,000 are diagnosed with MM each 
year. The average age at diagnosis is 65 to 70 years. 
The annual incidence of myeloma in the UK is 
approximately 60-70 per million. Myeloma has a 
higher incidence in Afro-Caribbean ethnic groups 
than in Caucasians but there are few other distinctive 
epidemiological features.
Criteria for Diagnosis — the Diagnosis of
Symptomatic MM requires the Following:
 M protein in the blood or urine, plus
 A bone marrow aspirate or biopsy showing that at least  
 10 per cent of the cells are plasma cells or the presence  
 of a plasma cell tumour (called a plasmacytoma), plus
 Evidence of damage to the body as a result of 
 the plasma cell growth, such as high calcium in 
 the blood, renal failure, anemia or destructive 
 bone lesions (CRAB)
Investigation of a patient with suspected myeloma 
should include the screening tests indicated followed 
by further tests to confi rm the diagnosis. We at 
Clinical Chemistry department performing various 
biomarkers for the screening and diagnosis of 
multiple myeloma. 
Screening Tests
Serum and urine protein electrophoresis                                     
Among the laboratory methods available for the 
separation of proteins, electrophoresis is a well-
established and versatile technique widely used in 
clinical chemistry. Protein electrophoresis of serum 
and urine is a sensitive means of detecting the 
abnormal monoclonal proteins found in myeloma. 
The test can identify intact immunoglobulin or free 
light chains in about 98 per cent of the cases.
tumour marker elevation is also known to occur in 
other confounding situations like smoking, ethanol 
consumption, COPD, etc., especially if there has 
been a recent change in habits.
Usually multiple tumour markers are associated 
with individual malignancy; vice versa, individual 
tumour markers may be associated with various 
malignancies. Thus the use of multiple markers 
based on the combination pattern for the selected 
malignancy will improve sensitivity and specifi city 
of the detection.
Conclusion
The use of tumour markers in clinical oncology has 
increased tremendously with rapid expansion of 
techniques of detection and identifi cation of new 
markers in recent times, a trend that continues to 
grow as technology progresses and our understanding 
about our body and the disease processes increases. 
However, such use is not without its pitfalls; in fact, 
injudicious application of tumour markers is fraught 
with risks of mistreatment (under-treatment or over-
treatment) and its consequences. Of the numerous 
tumour markers identifi ed, described and extensively 
researched upon, only a handful of them are used in 
routine clinical practice; and even of these, only a 
few have established consensus guidelines for use in 
day- to-day care of patients.
Judicious application of tumour markers to clinical 
practice needs a thorough understanding of the basics 
of pathophysiology, the techniques of identifi cation 
or testing, reasons (in cases of both benign and 
malignant tumours) for out-of-range levels of tumour 
markers, as well as the knowledge of evidence of 
their role in any given malignancy.
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During electrophoresis of serum proteins, intact 
monoclonal immunoglobulin molecules will migrate 
as a sharply defi ned band. (Figure 1) This is called a 
paraprotein, and is detected in about 80 per cent of 
patients with myeloma. It is almost always found in 
association with Bence-Jones protein in the urine. 
Bence-Jones protein is a homogeneous kappa or 
lambda free light chain.
In most of the remaining 20 per cent of cases of 
myeloma where a paraprotein is not detected in the 
serum electrophoretogram, monoclonal light chains 
are readily detected by protein electrophoresis of 
concentrated urine. This form of myeloma is usually 
referred to as Bence-Jones myeloma.
Quantifi cation of Non-Isotypic Immunoglobulins
Measuring total concentrations of IgG, IgA and 
IgM in serum can reveal elevation of a specifi c 
immunoglobulin isotype that is suggestive of the 
presence of a paraprotein. However, the test does 
not distinguish between the normal polyclonal 
and abnormal monoclonal forms of a particular 
immunoglobulin. This test is therefore not a 
substitute for the serum electrophoretogram for 
identifying the presence of a paraprotein in screening 
for myeloma.
Serum Urea, Creatinine, Calcium & Albumin
Many patients with myeloma have myeloma-related 
organ impairment (ROTI) in which corrected serum 
calcium of usually >0.25mmol/l above the upper 
limit of normal or >2.75mmol/l and serum creatinine 
of 1.9 mg/dl is suggestive of ROTI.
Tests to Establish Diagnosis
Immunofi xation electrophoresis (IFE) of serum and 
urine:
Identifi cation of the immunoglobulin isotype 
of a paraprotein by immunofi xation of the 
paraprotein band enables it to be classifi ed as an 
immunoglobulin G (IgG), immunoglobulin A (IgA) 
or immunoglobulin M (IgM) molecule. (Figure 2) 
Other isotypes are extremely rare. The identity of 
the isotype is important in differentiating whether 
production of the paraprotein is by a clonal plasma 
cell disorder, or by a clonal lymphoproliferative 
condition.      
IgG and IgA paraproteins suggest a clonal 
plasma cell disorder. In myelomas which 
produce paraproteins, IgG paraproteins occur in 
approximately 75 per cent, and IgA paraproteins 
in the remaining 25 per cent of cases. An IgM 
paraprotein is extremely uncommon in myeloma. 
It is more indicative of a clonal lymphoprolifer 
ative disorder, such as low-grade non-Hodgkin’s 
lymphoma. Waldenstrom’s macroglobulinaemia is 
an example of one form of low-grade non-Hodgkin’s 
lymphoma that is characteristically associated with a 
serum IgM paraprotein.
Figure 1: Monoclonal Gammopathy on Serum Protein Electrophoresis
(AKUH Lab)
Figure 2: Typing of Immunoglobulins on Immunofi xation Electrophoresis
(AKUH Lab)
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1p/19q Deletion: Favourable Prognostic 
Marker for Oligodendroglioma
Multiple chromosome abnormalities are reported in 
solid tumours, but the major challenge has been to 
separate critical and irrelevant events. Fluorescence 
in situ hybridization has emerged as an extremely 
important tool for detection and characterization of 
nonrandom chromosome aberrations in cancer. FISH 
results are utilized for a better understanding of the 
biological behaviour of the tumour, and to assist in 
determining the correct therapeutic approach. 
Oligodendrogliomas is the third most common 
glial neoplasm. It can grow in different parts of the 
brain, but most commonly found in the frontal or 
temporal lobes of the cerebrum. The frontal lobes 
are responsible for cognitive thought processes 
(knowing, thinking, learning, and judging). The 
temporal lobes are responsible for coordination, 
speech, hearing, memory, and awareness of time.
There are two types of oligodendroglioma: the 
well-differentiated tumour, which grows relatively 
slowly and in a defi ned shape; and the anaplastic 
oligodendroglioma, which grows much more rapidly 
and does not have a well-defi ned shape. Anaplastic 
oligodendrogliomas are much less common than 
well-differentiated oligodendrogliomas. 
Sony Siddiqui
Histopathology/Molecular Cytogenetics
More common than either form of pure 
oligodendroglioma is the mixed glioma, or 
oligoastrocytoma. These mixed gliomas are a 
mixture of oligodendroglioma and astrocytoma.
Role of 1p/19q as a Prognostic Marker
Among the various candidate biomarkers in gliomas, 
the 1p 19q codeletion in oligodendroglioma 
probably constitutes the best-characterized and 
most extensively investigated marker up to date. 
Loss of chromosome 1p and 19q is commonly 
seen in Oligodendroglioma but is rare in other 
tumour types, such as astrocytomas. The 1p/19q 
deletion test is useful in tumours with a complex 
“hybrid” morphology requiring differentiation 
from pure astrocytomas to support the presence of 
oligodendroglial differentiation/lineage. 
FISH Assay
Specimens from biopsies, excisions or resections of 
tumours received for FISH assay are handled as soon 
as possible to preserve tissue morphology. Specimens 
should be preserved in 10 per cent neutral-buffered 
formalin (NBF), preferably as 3-4 mm blocks 
Tests to Estimate Tumour Burden and Prognosis
Quantifi cation of Monoclonal Protein in Serum 
and Urine
The serum paraprotein concentration can be used 
for differentiating between the conditions. 
Concentrations below the threshold value are 
more likely to be monoclonal gammopathy of 
uncertain significance and those above are more 
likely to be myeloma. These values are IgG 
paraprotein disorders 30 g/L and IgA paraprotein 
disorders 20 g/L.
Patients with Bence-Jones myeloma have very 
low serum concentrations of the protein. 
However, they usually excrete more than 1 g of 
Bence-Jones protein in a 24-hour collection of 
urine.
ßeta-2 Microglobulin
Beta-2 microglobulin (B2M) is a useful tumour 
marker for some blood cell cancers, for detecting 
kidney damage, and for distinguishing between 
glomerular and tubular disorders of the kidney. As 
a tumour marker B2M test help to determine the 
severity and spread (stage) of multiple myeloma 
and may sometimes be ordered to evaluate the ef-
fectiveness of treatment. B2M has been associated 
with tumour burden, the amount of cancer present, 
and may be ordered to help evaluate the prognosis 
of cancers such as leukemia and lymphoma.
12
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fi xed for 18-24 hours followed by dehydration 
and embedment in paraffi n, for evaluation of 1p 
and 19q deletions, tumour areas need to be pre-
selected under the light microscope. Adequate areas 
should contain more than 60 per cent of tumour cell 
infi ltration, and no necrosis or hemorrhage. FISH 
analysis is performed using a dual-color approach 
for chromosomes 1 and 19 separately. Target probes 
hybridize to subtelomeric 1p36 and 19q13.3 in 
combination with control probes on 1q and 19p, 
respectively.
The assay is designed with one FISH probe for the 
long arm of the chromosome (q) and a second probe 
for the short arm (p). 
A                                  LSI 1p36 Region  
                                     
 
  Centromere                                                                                                         Telomere 
 
                                                    EGFL3                               TP73                                
                                                                                                          
                                               ~400 kb                             
B                               LSI 19q36 Region  
                                     
 
 
Centromere                                                                                                               Telomere   
                                                                                                                        
                                         ZNF44                         ZK1                        MAN2B1 
 
                                                ~500kb                               
 Figure 1: (A) shows target probe for 1p36; (B) shows 
target probe for 19q13.
1
LSI1p36  
LSI1q25 
19
LSI 19p113  
          
          
LSI19q13
Interpretation
A normal, undeleted case will show two orange and 
two green signals per cell while a deletion will have 
only one orange signal and two green signals.  
Detecting 1p and 19q deletions are both 
diagnostic and predict a favourable response 
to therapy. Research has shown that anaplastic 
oligodendroglioma patients who have a loss of 
heterozygosity on chromosome 1p, or a combined 
loss of heterozygosity on chromosomes 1p and 
19q survive longer (an average of ten years), than 
patients with tumours that lack these genetic changes 
(an average of two years).
Therapy
The standard treatment for all grades of 
oligodendrogliomas is surgery to remove the tumour 
completely. Oligodendrogliomas are among the only 
brain tumours that can be successfully treated with 
a type of chemotherapy called PCV (Procarbazine, 
CCNU or lomustine, and Vincristine). Chemotherapy 
is usually used only in cases of recurrent anaplastic 
oligodendrogliomas. For patients with well-defi ned 
oligodendrogliomas, median survival exceeds ten 
years. For patients with anaplastic dendrogliomas, 
median survival ranges from two to fi ve years.
Figure 2: FISH images show tissue sections, hybridized to 1p19q dele-
tion probe. In images A and C orange signal is lost indicating deletion 
of 1p and 19q respectively; Image B shows two orange and two green 
signals indicating copies of both the chromosomes.
(AKUH Lab)
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Non-small cell lung cancer (NSCLC) accounts 
for about 85 per cent of lung cancers and includes 
predominantly adenocarcinomas (the most common 
type) and squamous cell carcinomas.
Type of Lung Cancer Percent of NSCLC
Adenocarcinoma 40-50 per cent
Squamous 30-35 per cent
Large Cell 10-20 per cent 
Significant progress has been made during the 
last 20 years in the molecular characterization of 
lung tumours. Mutational status in non-small-cell 
lung cancer is critically important in determining 
the most effective therapy. EGFR (Epidermal 
Growth Factor Receptor), KRAS and EML4-
ALK (anaplastic lymphoma kinase) are fusion 
genes; status for these biomarkers in NSCLC is 
becoming an integral component in treatment 
decisions. 
Traditionally, non-small-cell lung cancers were 
classified according to their histological features. 
Various driver mutations have been associated 
with these cancers over time. The mutations 
are mutually 
exclusive, as 
shown in Figure 1 
EGFR mutations 
are found in 15 per 
cent of cases from 
North America, 
Western Europe, 
but are reported 
in 30–50 per cent 
of patients of East 
Asian descent with 
adenocarcinomas 
with ronchoalveolar 
features that 
arise among 
non-smokers. 
Toheed Kausar
Molecular Pathology
EGFR Mutation Screening Test
Overall, KRAS mutations have been reported in 
30–50 per cent of patients with adenocarcinoma 
histology. Whereas the frequency of EML4-
ALK translocation ranges from 3 to 7 per cent in 
unselected NSCLC.
EGFR Basics
EGFR (Epidermal Growth Factor Receptor) is 
a cell-surface receptor tyrosine kinase, which 
upon ligand binding leads to activation of 
various downstream signaling pathways. EGFR 
is linked to cell growth, proliferation, survival 
and migration. Clinical studies have shown 
that a subset of NSCLC patients harbors EGFR 
mutations (Figure 2), and nearly 85 per cent 
of those patients benefit from tyrosine kinase 
Figure 1: Recurrent Mutations in NSCLC
Figure 2: Important EGFR kinase domain mutations (exons 18 to 21)
Table: 1. Frequency of NSCLC in different types of lung 
cancer
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inhibitors (TKI) therapy. Furthermore, EGFR 
mutations are found associated with response 
to gefitinib and erlotinib TKI, and prolonged 
survival in NSCLC patients.
EGFR Mutation Analysis
The Molecular Pathology Section, The Aga Khan 
University Hospital Clinical Laboratory, AKUH 
accepts formalin fi xed paraffi n embedded tissue 
(FFPET) blocks for EGFR mutational analysis. 
Briefl y, genomic DNA extracted from FFPET 
section is PCR amplifi ed using in Real Time PCR 
chemistry (Figure 3). The assay can detect 41 
different mutations in four exons (18-21) of EGFR 
gene including several point mutations, deletions and 
insertions. Currently, EGFR is validated for biopsies 
of NSCLC.
Signifi cance of EGFR Mutation Analysis
The prevalence of EGFR mutations in unselected 
cases of NSCLC is approximately 10 per cent.
The clinical responses to TKI were shown to be 
associated with EGFR mutations. However these 
mutations occur most frequently, but not exclusively, 
in non-smoking/ light-smoking female patients of 
Asian ancestry with adenocarcinoma histologies.
Clinical data indicate that patients with advanced 
NSCLC tumours harboring activating mutations 
of EGFR, which occur most commonly as 
deletions in exon 19 or as the L858R point 
mutation in exon 21, exhibit a high response rate 
and prolonged progression-free survival (PFS) 
when treated with anti-EGFR TKIs, both in first- 
and second-line therapy. Other less common 
EGFR mutations, such as G719X substitutions in 
exon 18 and the L861Q point mutation in exon 
21 also predict for responsiveness to anti-EGFR 
therapies. Median survival in patients with EGFR-
mutant NSCLC treated with anti-
EGFR TKIs is now approximately 
two years.
But some patients would 
eventually develop resistance to 
these TKIs. Subsequent studies 
found that a secondary mutation in 
the EGFR gene (T790M mutation) 
could be the main resistance 
mechanisms involved. T790M 
mutation, which is thought to 
cause steric hindrance and impair 
the binding of gefitinib/erlotinib. The T790M is 
present as a minor allele before TKI therapy and 
accounts for about half of the acquired resistant 
cases. 
The future of molecular testing and adoption of 
personalized treatments in NSCLC would depend 
upon identifi cation of new biomarkers and their 
potential inhibitors. In addition, implementation 
of routine testing of known biomarkers associated 
with specifi c treatments (EGFR, ALK) and our 
understanding for causes of tumour resistance would 
create resource for novel therapeutic strategies.  
Figure 3: Workfl ow of EGFR Mutation Analysis Protocol.
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Introduction
 
Chronic myeloid leukemia (CML) is a chronic 
hematopoietic stem cell disorder characterized 
by extensive proliferation and expansion of 
myeloid cells at varying stages of maturation and 
differentiation. The Philadelphia (Ph) chromosome 
(Figure1) is a hall mark of CML and results from 
the reciprocal translocation between nine and twenty 
two, creating a fusion gene consisting of break point 
cluster region and Abelson proto-oncogene (BCR-
ABL) with constitutive tyrosine kinase activity 
resulting in myeloid proliferation.
Imatinib mesylate (Glivec) is currently the standard 
of care for CML. Glivec is a tyrosine kinase inhibitor 
(TKI) which induces durable responses in the 
majority of CML patients. The overall survival of 
CML patients with complete cytogenetic response 
is reaching up to 85 per cent at end of seven year’s 
follow-up period.  
Mechanism of Imatinib Resistance
Lately, imatinib resistance has become a 
significant problem in the management of CML 
patients. Mutations in the BCR-ABL1 Kinase 
Domain gene are the most commonly reported 
mechanism of acquired resistance to imatinib 
leading to shortened survivals of CML patients. 
The frequency of mutation is found to be much 
higher in the acute phase/blast crisis phase as 
compare to chronic phase.
Imatinib resistance due to BCR-ABL1 Kinase 
Domain mutations may arise through a variety 
of mechanisms. The most common cause of 
resistance is a conformational change in protein 
which results from mutation in Kinase Domain 
drug binding site specifically P-loop or ATP 
binding region.
Types of BCR-ABL1 Kinase Domain Mutations
To date about ninty different mutations (Table 
2) in Kinase Domain which are associated with 
resistance to TKI have been identified. Mostly 
mutations are clustered within nine amino acid 
positions on KD genes including T315I, Y253H/F, 
M351T, G250E, E255K/V, F359V, and H396R. 
Some of these mutations are found to result in 
resistance to Imatinib and also second line TKIs 
such as Dasatinib and Nilotinib. For example, the 
T315I mutation is the most common KD mutation 
associated with resistant to all generation of 
TKI therefore screening for T315I mutation is 
recommended for all CML patient undergoing 
treatment.
Clinical Utility of BCR-ABL1 Kinase Domain 
Mutational Analysis
Nazneen Islam
Molecular Pathology 
Figure 1: Chromosomal Translocations t (9; 22) (q34; q11.2)
Graph 1. Frequency of different BCR-ABL kinase Domain 
Mutation
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In acute myeloid leukemia (AML), various 
approaches have been used to characterise 
minimal residual disease (MRD) such as, 
immunophenotyping, cytogenetic and molecular 
analysis. Unfortunately, the methods with higher 
sensitivity (i.e. molecular based tests) may be 
hampered by the lack of a specific target marker. 
A majority of AML cases, do not have a specific 
cytogenetic and ⁄ or molecular alteration that can 
be used as a reliable or appropriate marker of 
MRD after morphological remission. The Wilms’ 
tumour gene (WT1) was first cloned in 1990. 
During embryogenesis the WT1 gene encodes 
a protein which plays a critical role in normal 
development of the kidney, gonads, spleen and 
heart. It also identified as an onco-suppressor 
gene which encodes a transcription factor that 
plays a fundamental role in the development of 
Wilms’ tumour. Moreover, it is now evident that 
WT1 gene values correlate with disease status, 
Utility of Wilms’ Tumour Expression in 
Minimal Residual Disease
Dr Zeeshan Ansar Ahmed and Samina Ghani
Molecular Pathology
thus being a good candidate for the evaluation 
of MRD, especially in the relevant percentage of 
patients who lack a specific molecular marker of 
their disease.
The WT1 gene is present on chromosome 11p13q 
and consists of 10 exons. It encodes a transcription 
factor that required for normal cellular development 
and cell survival. This gene is highly expressed in 
several hematopoietic malignancies  for example 
acute myeloid leukemia, acute lymphoblastic 
leukemia, chronic myeloid leukemia in blast crisis, 
myelodysplastic syndrome and lymphomas. It 
also over expressed in various other types of solid 
tumours likes melanoma, lung, breast, testicular and 
ovarian cancers.
In the majority of adult patients with leukemia it is 
possible to achieve a complete remission (CR).  In 
the case of AML, 60-80 per cent of patients reach CR 
Molecular uL/uu/LL Based Diagnosis for BCR-
ABL Kinase Domain Mutations
The Molecular Pathology section, Clinical 
Laboratories, AKUH offer DNA sequencing for the 
detection of BCR-ABL Kinase domain mutations 
(Figure 3). In this method RNA is extracted and 
converted to complementary DNA using a reverse 
transcriptase enzyme. Complementary DNA is 
subjected to PCR amplifi cation using primers that 
amplify 716 bp regions of KD gene resulting in 
the formation of a specifi c PCR product. The PCR 
product is sequenced using an automated capillary 
electrophoresis DNA sequencer and the resulting 
nucleotide sequence is analyzed for the presence 
of mutations using the Mutation Surveyor software 
(SoftGenetics, USA).
When to Look for BCR-ABL1 Kinase Domain 
Mutations
Summary of cases in which BCR-ABL kinase 
Domain mutation analysis is recommended
At Diagnosis
Only in acute phase/blast crisis phase 
During First Line Imatinib Therapy
In case of failure
In case of major molecular response loss
In case of suboptimal response
During second Line Dasatinib or Nilotinib Therapy
 In case of hematologic and cytogenetic failure
Figure 3: Detection of BCR-ABL kinase domain mutations by direct DNA 
sequencing.
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however; the majority of these patients subsequently 
relapse. Currently, there is an effort to predict relapse 
by MRD and subsequently to begin the treat¬ment 
during clinical and hematological remission prior to 
overt hematological relapse. Treatment of MRD has 
a greater probability of success, is less distressing 
for the patients and also has a lower cost than the 
treatment of a probable hematological relapse. 
Consequently, the WT1 gene is a suitable candidate 
as a marker for monitoring MRD in AML, either 
in bone marrow or in PB, particularly in patients 
without specifi c molecular markers. 
The molecular techniques, based on an analysis of 
nucleic acids, appear to be most useful for MRD 
monitoring. Molecular techniques are highly 
specifi c and in connection with polymerase chain 
reaction (PCR) also very sensitive. These techniques 
enable the detection of a prolifera¬tion of the 
leukemic clone weeks or several months prior 
to the hematological relapse, when the patient is 
still in hematological and clinical remission. The 
appropriate marker for MRD monitoring should 
be over expressed minimally two logs higher in 
diagnostic samples compared to those from normal 
healthy individuals. Therefore, estimation of the 
level of the WT1 expression could be benefi cial 
for predicting hemato¬logical relapse. As the WT1 
gene is often expressed in patients in permanent 
remission, it was necessary to establish an upper 
remission limit which, when exceeded, signals a 
high risk of hematological relapse. In fact, the upper 
remission limit defi nes the molecular relapse level.
However, a persistently elevated WT1 level 
following therapy is predictive of poor outcome. 
In addition, it has been demonstrated that normal 
hematopoietic recovery following chemotherapy 
does not signifi cantly modulate WT1 expression 
levels. Monitoring of disease status with WT1 
affords the opportunity to include more AML 
patients in a single assay than any other leukemic 
marker and has a potential role in MRD monitoring 
of patients that are cytogenetically normal.
Method for detection of WT1 expression 
For WT1 analysis, RNA is extracted from peripheral 
blood or bone marrow of diagnosed cases of AML 
and complementary DNA is synthesized. This cDNA 
is used for PCR using specifi c primers to the WT1 
gene along with standards and controls to determine 
WT1 expression.
Figure 1. Differential WT1 expression in AML cases as compared with 
healthy controls. Relative expression of the WT1 gene in peripheral 
blood of normal healthy donors and AML patients at diagnosis. The bars 
represent medians and the boxes represent 25th to 75th  percentiles of 
WT1 expression.
Cytogenetic Testing for Acute Myeloid Leukaemia
Marium Ghani
Histopathology/Molecualr Cytogenetics
Acute myeloid leukaemia (AML) is a type of 
cancer that affects immature blood cells on the 
myeloid cell line leading to neutropenia, anemia, 
and thrombocytopenia. Differentiation and 
treatment of acute leukaemias require specialist 
techniques including cytochemical staining, 
immunophenotyping and chromosome studies 
(cytogenetics).
Laboratory Tests used to Diagnose Acute Myeloid 
Leukaemia
One or more of the following lab tests may be done 
on the samples to diagnose AML and/or to determine 
the specifi c subtype of AML.
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Morphology: Blood and marrow smears are 
morphologically examined using a May-
May-Grünwald-Giemsa or a Wright-Giemsa stain.
Immunphenotying: Multiparameter (commonly at 
least three to four color) fl ow cytometry is used to 
determine lineage involvement of a newly diagnosed 
acute leukemia.
Conventional cytogenetics: Conventional 
cytogenetics analysis is a mandatory component in 
the diagnostic evaluation of a patient with suspected 
acute leukemia. A minimum of 20 metaphase cells 
are analyzed from bone marrow/ blood which is 
considered mandatory to establish the diagnosis of 
a normal karyotype, and recommended to defi ne an 
abnormal karyotype. 
Molecular cytogenetics: Methanol/acetic acid–
fi xed cell pellets should be stored so if cytogenetic 
analysis fails, fl uorescence in situ hybridization 
(FISH) is an option to detect gene rearrangements, 
such as RUNX1-RUNX1T1, CBFB-MYH11, MLL 
and EVI1 gene fusions, or loss of chromosome 5q 
and 7q material. FISH analysis 
has several advantages over 
chromosome studies. It has a 
rapid turnaround time, detects 
small numbers of abnormal cells, 
and can also be performed on 
non-dividing (interphase) cells. 
It can detect cryptic or subtle 
rearrangements that might be 
diffi cult to detect by routine 
karyotyping. In addition, FISH is 
frequently necessary to identify 
MLL fusion partners in 11q23 
translocations.
Molecular genetics: Molecular 
diagnosis by reverse 
transcriptase–polymerase 
chain reaction (RT-PCR) for the 
recurring gene fusions, such as RUNX1-RUNX1T1, 
CBFB-MYH11, MLLT3-MLL, DEK-NUP214, and 
somatically acquired mutations in several genes, 
for example, the NPM1 gene, the FLT3 gene, the 
CEBPA gene,  myeloid/lymphoid or mixed-lineage 
leukemia (MLL) gene, the neuroblastoma RAS viral 
(v-ras) oncogene homolog (NRAS) gene, the Wilms 
tumour 1 (WT1) gene, the v-kit Hardy-Zuckerman 
4 feline sarcoma viral oncogene homolog (KIT) 
gene,  runt-related transcription factor 1 (RUNX1) 
gene, the tet oncogene family member 2 (TET2) 
gene, and the isocitrate dehydrogenase 1 (NADP+), 
soluble (IDH1) gene can be useful in certain 
circumstances.
Genome-wide studies: Recent progress in genomics 
technology has resulted in the identifi cation of 
novel genetic abnormalities and holds the promise 
of making the systematic characterization of cancer 
genomes feasible. It includes gene- and microRNA-
expression profi ling and single nucleotide 
polymorphism (SNP)-based mapping arrays.
Prognostic Information for Patients with Acute 
Myeloid Leukaemia
The outcome for patients with AML depends on 
a variety of factors including age of the patient, 
intensity of postremission therapy, biologic 
characteristics of the disease and the most important 
of which are the cytogenetics at presentation. 
Results of cytogenetic analysis at diagnosis provide 
important prognostic information in AML and aids in 
monitoring response to therapy or progression of the 
disease. Following are the cytogenetics risk groups 
which can be found in patients with AML:
AML Panel by FISH Offered by the Clinical 
Laboratory
For FISH testing, a sodium-heparin (green-top) tube 
with 3–4 ml of blood/ bone marrow is required. 
Samples should be stored at room temperature and 
transported to the laboratory within 24 hours of draw. 
Bone marrow cells on unstimulated cultures either 
from direct harvest or 24 hour culture are analyzed 
by FISH using a set of commercially available FISH 
probes (Vysis, Abbott). Each probe can be run as a 
part of the panel or individually. Following are the 
Ref: Grimwade et al, Blood 1998;92:2322-2333
Abnormality
t(8;21) t(15;17) inv(16)
Normal +8 +21 +22 del(7q) 
del(9q) Abnormal 11q23 All 
other structural/numerical 
abnormalities
−5 −7 del(5q) Abnormal 
3qComplex
Risk Group
Favorable
Intermediate
Adverse
Comment
Whether alone or in 
conjunction with other 
abnormalities.
ie, Cytogenetic abnormali-
ties not classifi ed as favor-
able or adverse. Lack of ad-
ditional favorable or adverse 
cytogenetic changes.
Whether alone or in con-
junction with intermediate-
risk or other adverse-risk 
abnormalities.
19
VOL. 39, ISSUE 1SEPTEMBER 2013
Figure 1: G-banded karyotype with t(15;17)(q22;q21) at arrows (Wakim 
et al. 2012).
Figure 2: Dual-color Dual-fusion translocation probe for the detection 
of  PML-RARA fusion. Panel A shows a normal FISH pattern (2R, 2G), 
whereas panel B reveals fusion of the PML and RARA loci at arrows. 
(Clinical Laboratory)
FISH probes available at the cytogenetics laboratory 
of the AKUH and can be requested for AML:
t(8;21): AML with t(8;21)(q22;q22) is seen most 
often in patients with M2 and is defi ned by the 
presence of this translocation, a variant translocation, 
or molecular RUNX1-RUNX1T1 fusion.
t(15:17): AML with t(15;17)(q22;q21)/PML-RARA 
is a distinct clinicopathologic entity defi ned by the 
presence of the PML-RARA fusion and is seen most 
often in patients with M3  (Figure 1 and Figure 2).
t(11q23:var): AML with t(9;11) is seen in patients 
with M0-M7 subtypes and is the only translocation 
involving the MLL gene included as a distinct 
biologic subtype. Although >60 fusion partner 
genes are known for MLL, the more common 
translocations in AML include 6q27 (MLLT4), 10p12 
(MLLT10), 19p13.1 (ELL), and 19p13.3 (MLLT1), 
all resulting in fusion genes.
inv(16): AML with inv(16)/t(16;16) is seen most 
often in patients with M4 and is  defi ned by the 
translocation and/or molecular fusion of CBFB and 
MYH11.
+8: Trisomy eight in AML occurs in patients with 
M0-M7 subtypes either as the sole anamoly or 
together with other clonal chromosome abberations.
-7/7q deletion: is frequent in secondary MDS 
or AML, and also in leukemias occurring in 
individuals with constitutional syndromes including 
predisposition to myeloid disorders.
-5/5q deletion: Deletion of 5q can be observed in 
both de novo and therapy related AML. It is also 
seen as monosomy fi ve. In AML, 5q deletion is 
usually associated with a complex karyotype. The 
most commonly observed interstitial deletions are 
del(5)(q13q31), del(5)(q13q33), and del(5)(q22q33), 
forming a commonly deleted region (CDR) at 
5q31-q32.
Diffuse Large B-Cell Lymphoma Subgroups 
have Different Phenotype
Dr Shahid Pervez & Dr Arsalan Ahmed
Histopathology,
Diffuse large B-cell lymphoma is the most 
common lymphoma subtype, accounting for 30 
per cent of all non-Hodgkin’s lymphomas (NHL). 
It shows an aggressive clinical course, and 
comprises a heterogeneous group of lymphomas 
in terms of morphology, immunophenotype and 
molecular abnormalities.
DLBCL, NOS includes three common 
morphologic variants (centroblastic, 
immunoblastic and anaplastic) plus rare 
morphologic variants. These variants are 
important for pathologist to recognize so they 
are not misdiagnosed as either indolent or 
lymphoblastic lymphomas.
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DLBCL can also be divided based on cell of 
origin.   The WHO lists two molecular and IHC 
subgroups:  Germinal center-like (GCB) and 
non-germinal center-like (non-GCB) subgroups.  
Gene-expression profiling studies have 
distinguished three molecular subtypes of DLBCL 
known as ‘‘germinal center B-cell-like’’ (GCB), 
‘‘activated B-cell-like’’ (ABC), and ‘‘primary 
mediastinal B-cell lymphoma’’ (PMBL).  GCB 
DLBCLs seem to arise from normal germinal 
center B cells, ABC DLBCLs may arise from 
Figure 1: Four immunostaining algorithms used to assess differentiation profi le (GCB vs non-GCB) in patients with DLBCL.
postgerminal center B cells that are arrested 
during plasmacytic differentiation, and PMBLs 
may arise from thymic B cells.
Since gene expression profiling (GEP) has 
remained as an impractical clinical tool, a number 
of immunohistochemical algorithms have been 
proposed to translate GEP classification into 
a manageable set of measurable proteins to 
distinguish between GCB and non-GCB type 
DLBCL. (Figure 1)
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The best know is “Hans algorithm”.  According to 
this algorithm, GC group is CD10+ and/or BCL6+, 
MUM-1-.  The non-GCB group is CD 10-, BCL6+, 
MUM1+ or CD10-, BCL6-.  There are some unre-
solved issues attached to this algorithm.  First, not 
everyone interprets the GC group in the same way.  
According to some, both CD10 and BCL6 should 
be positive, while some believe either is fi ne, but 
MUM1 and CD138 should be negative.  Secondly 
not everybody will fi nd that GCB group does better 
than non-GCB group. (Figure 2)
This algorithm, however, was designed for use 
in patients treated with CHOP without rituximab 
(pre-rituximab era), and in addition, it had low 
concordance with GEP analysis (71 per cent for 
Figure 2: (A): Diffuse Large B-cell Lymphoma (DLBCL) (H&E), (B) 
DLBCL stained with anti-CD10 antibody with strong diffuse cytoplasmic 
staining consistent with ‘Germinal Centre (GC) phenotype’, (C) DLBCL 
stained with anti-Bcl6 antibody showing strong nuclear staining 
consistent with GC phenotype, (D) DLBCL stained with anti-MUM1 
antibody showing strong diffuse nuclear staining consistent with ‘Post-
Germinal Centre phenotype. (Courtesy: AKUH Lab)
GCB, 88 per cent for non-GCB). The prognostic 
relevance of the Hans algorithm led to inconsistent 
results in subsequent studies performed in patient 
groups treated with R-CHOP.  Nevertheless, the 
Lymphoma/Leukemia Molecular Profi ling Project (L/
LMPP) has demonstrated the GCB group still does 
better than the non-GCB group in the “R-CHOP” 
era.  The literature remains inconsistent and 
indecisive.  Some studies have shown that the GCB 
group  did better than the non-GCB group when 
CHOP therapy was used but no differences could 
be seen with R-CHOP, while some have 
reported that GCB did no better than non-
GC group after treatment  with R-CHOP.  
Others have reported no differences even in 
the CHOP era.  There is a newer algorithm 
(Choi and coworkers) that compared to the 
their Hans algorithm improves concordance 
with the gene expression profi ling data from 
86 per cent to 93 per cent using GCET1 
and FOXP1 antibodies in addition to CD10, 
BCL6 and MUM1.  
Newer algorithms have also been 
proposed which include Tally algorithm 
and the latest algorithm was proposed 
in International DLBCL Rituximab-
CHOP Consortium Program Study.  This 
latter algorithm boasts to have a simpler 
structure than other recently proposed 
algorithms and is based on the expression of 
CD10, FOXP1, and BCL6 and has a 92.6 per cent 
concordance with GEP.
Others who recently tested multiple algorithms 
suggest that none work and what you really need are 
gene expression profi ling studies, unfortunately an 
impractical suggestion.  In the end we believe that 
more work has to be done in this fi eld and that one 
should still be careful in using these algorithms for 
determining prognosis between GCB and non-GCB 
DLBCL subgroups.
A
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The 1st Joint Conference of Pakistan Association 
of Pathologist (PAP) and Societies of Pathologists 
was held in Islamabad from 7th - 9th Dec 2012. 
This conference was hosted by Armed Forces 
Institute of Pathology (AFIP) at the Convention 
Centre Islamabad. The conference excelled in 
presenting exciting developments in the field 
of pathology and laboratory medicine; some of 
the highlights are reported here. Preconference 
workshops of Histopathology, Haematology, 
Microbiology, Chemical Pathology and 
Immunology were conducted by the hosting 
institute. The goal was to facilitate participants 
in exploring new areas in respective fields at an 
interactive learning forum.
Pathologists, trainees and laboratory personnel 
from all over Pakistan and abroad attended 
this conference. The first day began with 
inauguration ceremony on evening of 7th 
December followed by the ‘Razi lecture’, given 
by Professor Aw Tar Choon, from Singapore 
on ‘Clinical application of circulation tumor 
cells’. Jabir Ibn Hayyan lecture was given by 
Dr DP Mikhailidis from United Kingdom, who 
highlighted on cardiovascular risk assessment 
and emphasized on utility of risk prediction 
tools. Evening ended with a banquet dinner and 
Mehfil-e-Hamd o Naat.
Second day December 8, 2012 started with Ibn-e-
Sina lecture given by Prof Dr Lawrence Faulkner 
from United Kingdom on role of international 
NGOs to improve access to cure and prevention 
of hemoglobinopathies in developing countries, 
followed by plenary state-of-the-art lectures 
delivered by eminent pathologists from  United 
Kingdom. Guest speakers talked on range of 
topics from organ transplant, DNA testing to paper 
publication, which generated exciting discussions. 
These lectures were followed by plenary lectures in 
different disciplines of pathology given by Aga Khan 
University (AKU) faculty and other pathologists 
from Pakistan. Parallel scientifi c sessions of free 
papers gave participants including a large number 
of AKU residents great learning opportunity by 
sharing work on a national platform. Several selected 
abstracts were also displayed as posters which 
portrayed research advances in the fi eld of pathology. 
The scientifi c sessions were followed by banquet 
dinner.
The Third day conference was held at Barian, Murree. 
Day started by meet the experts’ sessions, a great 
learning opportunity for budding pathologists for 
learning from experts in their respective fi elds. This 
was followed by plenary sessions. The conference 
closing ceremony was in afternoon followed by a 
marvelous meal and lively social discussion. It was a 
wonderful way to fi nish the conference. Like always 
the conference was successful in bringing together 
delegates from the different disciplines of pathology 
and laboratory medicine and allowing opportunity for 
a healthy debate.
Meeting Report: 1st Joint Conference of PAP/ 
Societies of Pathologists and 36th  Annual 
Conference Pakistan Association of Pathologists
Reported by Dr Hafsa Majid
Resident, Chemical Pathology
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The fi rst Pathology and Microbiology Research 
Day of Aga Khan University Hospital was held 
on October 11, 2012 at Pearl Continental Hotel, 
Karachi. This event showcased original research 
studies from residents and faculty of Department of 
Pathology and Microbiology.
The programme started with recitation from Holy 
Quran, welcoming address was given by the 
department’s Chair Dr Naila Kayani followed by an 
introductory speech given by Chair of research day’s 
organizing committee, Dr M. Asim Baig. Residents, 
staff and junior faculty from all sections of Pathology 
and Microbiology shared their research work with 
their fellow trainees, faculty and other investigators 
via presentation of free papers and poster session. 
Renowned scientist of Pakistan Dr Atta-ur- Rahman 
was invited as guest speaker, who gave an enlighting 
talk on developments in the fi eld of research in 
Pakistan. This was followed by a talk given by 
Dean, Research and Graduate Studies AKU, Dr 
El-Nasir Lalani on need of developing research 
activities to help us achieve the challenges posed by 
accelerating scientifi c changes. Final address was 
by Dean, Medical College AKU, Dr Farhat Abbas 
who highlighted that the importance is not only to 
do research but also to get that research out to the 
scientifi c community. He also congratulated the 
organizers of the event for arranging a platform that 
provided the opportunity to budding researchers to 
present their work to a large scientifi c community. 
The program ended with certifi cate distribution and 
the participants were then provided the opportunity 
to interact with each other and the guests during dinner.
Pathology and Microbiology Research Day 
2012
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